Translational tidbits

Last month's public-private partnership with the highest total funding was the launch of the Global Health Innovative Technology Fund, an infectious disease initiative that plans to disperse $100 million over 5 years. On the biotech side, Onyx Pharmaceuticals Inc. formed an alliance with the University of California, San Francisco's Helen Diller Family Comprehensive Cancer Center.

A table of selected public-private partnerships (PPPs) announced in June rounds out this edition of translational tidbits (see "Selected public-private partnerships for June 2013").

Japan reaches out

The Global Health Innovative Technology Fund (GHIT Fund) launched its flagship funding program to partner Japanese pharmas and academics with Western not-for-profit organizations to conduct research on tropical and neglected diseases.

GHIT Fund's plan is to distribute about $100 million over 5 years for R&D in diseases that mostly occur outside of Japan, including tuberculosis, malaria and a range of tropical parasites.

About half of the committed funding comes from Japan's government, a quarter from the Bill

Read the full 1547 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE